BACKGROUND AND OBJECTIVE: Methylating agents are effective chemotherapy agents for Hodgkin lymphoma, but are associated with the development of second primary cancers. Cytotoxicity of methylating agents is mediated primarily by the DNA mismatch repair (MMR) system. Loss of MLH1, a major component of DNA MMR, results in tolerance to the cytotoxic effects of methylating agents and persistence of mutagenised cells at high risk of malignant transformation. We hypothesised that a common substitution in the basal promoter of MLH1 (position -93, rs1800734) modifies the risk of cancer after methylating chemotherapy. METHODS: 133 patients who developed cancer following chemotherapy and/or radiotherapy (n = 133), 420 patients diagnosed with de novo myeloid leukaemia, 242 patients diagnosed with primary Hodgkin lymphoma, and 1177 healthy controls were genotyped for the MLH1 -93 polymorphism by allelic discrimination polymerase chain reaction (PCR) and restriction fragment length polymorphism assay. Odds ratios and 95% confidence intervals for cancer risk by MLH1 -93 polymorphism status, and stratified by previous exposure to methylating chemotherapy, were calculated using unconditional logistic regression. RESULTS: Carrier frequency of the MLH1 -93 variant was higher in patients who developed therapy related acute myeloid leukaemia (t-AML) (75.0%, n = 12) or breast cancer (53.3%. n = 15) after methylating chemotherapy for Hodgkin lymphoma compared to patients without previous methylating exposure (t-AML, 30.4%, n = 69; breast cancer patients, 27.2%, n = 22). The MLH1 -93 variant allele was also over-represented in t-AML cases when compared to de novo AML cases (36.9%, n = 420) and healthy controls (36.3%, n = 952), and was associated with a significantly increased risk of developing t-AML (odds ratio 5.31, 95% confidence interval 1.40 to 20.15), but only in patients previously treated with a methylating agent. CONCLUSIONS: These data support the hypothesis that the common polymorphism at position -93 in the core promoter of MLH1 defines a risk allele for the development of cancer after methylating chemotherapy for Hodgkin lymphoma. However, replication of this finding in larger studies is suggested.
BACKGROUND AND OBJECTIVE: Methylating agents are effective chemotherapy agents for Hodgkin lymphoma, but are associated with the development of second primary cancers. Cytotoxicity of methylating agents is mediated primarily by the DNA mismatch repair (MMR) system. Loss of MLH1, a major component of DNA MMR, results in tolerance to the cytotoxic effects of methylating agents and persistence of mutagenised cells at high risk of malignant transformation. We hypothesised that a common substitution in the basal promoter of MLH1 (position -93, rs1800734) modifies the risk of cancer after methylating chemotherapy. METHODS: 133 patients who developed cancer following chemotherapy and/or radiotherapy (n = 133), 420 patients diagnosed with de novo myeloid leukaemia, 242 patients diagnosed with primary Hodgkin lymphoma, and 1177 healthy controls were genotyped for the MLH1 -93 polymorphism by allelic discrimination polymerase chain reaction (PCR) and restriction fragment length polymorphism assay. Odds ratios and 95% confidence intervals for cancer risk by MLH1 -93 polymorphism status, and stratified by previous exposure to methylating chemotherapy, were calculated using unconditional logistic regression. RESULTS: Carrier frequency of the MLH1 -93 variant was higher in patients who developed therapy related acute myeloid leukaemia (t-AML) (75.0%, n = 12) or breast cancer (53.3%. n = 15) after methylating chemotherapy for Hodgkin lymphoma compared to patients without previous methylating exposure (t-AML, 30.4%, n = 69; breast cancerpatients, 27.2%, n = 22). The MLH1 -93 variant allele was also over-represented in t-AML cases when compared to de novo AML cases (36.9%, n = 420) and healthy controls (36.3%, n = 952), and was associated with a significantly increased risk of developing t-AML (odds ratio 5.31, 95% confidence interval 1.40 to 20.15), but only in patients previously treated with a methylating agent. CONCLUSIONS: These data support the hypothesis that the common polymorphism at position -93 in the core promoter of MLH1 defines a risk allele for the development of cancer after methylating chemotherapy for Hodgkin lymphoma. However, replication of this finding in larger studies is suggested.
Authors: E Ito; Y Yanagisawa; Y Iwahashi; Y Suzuki; H Nagasaki; Y Akiyama; S Sugano; Y Yuasa; K Maruyama Journal: Biochem Biophys Res Commun Date: 1999-03-24 Impact factor: 3.575
Authors: Lois B Travis; Charles S Rabkin; Linda Morris Brown; James M Allan; Blanche P Alter; Christine B Ambrosone; Colin B Begg; Neil Caporaso; Stephen Chanock; Angela DeMichele; William Douglas Figg; Mary K Gospodarowicz; Eric J Hall; Michie Hisada; Peter Inskip; Ruth Kleinerman; John B Little; David Malkin; Andrea K Ng; Kenneth Offit; Ching-Hon Pui; Leslie L Robison; Nathaniel Rothman; Peter G Shields; Louise Strong; Toshiyasu Taniguchi; Margaret A Tucker; Mark H Greene Journal: J Natl Cancer Inst Date: 2006-01-04 Impact factor: 13.506
Authors: Sara J Schonfeld; Ethel S Gilbert; Graça M Dores; Charles F Lynch; David C Hodgson; Per Hall; Hans Storm; Aage Andersen; Eero Pukkala; Eric Holowaty; Magnus Kaijser; Michael Andersson; Heikki Joensuu; Sophie D Fosså; James M Allan; Lois B Travis Journal: J Natl Cancer Inst Date: 2006-02-01 Impact factor: 13.506
Authors: Sun Ha Park; Ga Young Lee; Hyo-Sung Jeon; Su Jeong Lee; Kyung Mee Kim; Sang Soo Jang; Chang Ho Kim; Won Kee Lee; Sin Kam; Rang Woon Park; In-San Kim; Tae Hoon Jung; Jae Yong Park Journal: Int J Cancer Date: 2004-11-20 Impact factor: 7.396
Authors: Lois B Travis; Deirdre A Hill; Graça M Dores; Mary Gospodarowicz; Flora E van Leeuwen; Eric Holowaty; Bengt Glimelius; Michael Andersson; Tom Wiklund; Charles F Lynch; Mars B Van't Veer; Ingrid Glimelius; Hans Storm; Eero Pukkala; Marilyn Stovall; Rochelle Curtis; John D Boice; Ethel Gilbert Journal: JAMA Date: 2003-07-23 Impact factor: 56.272
Authors: Lucy A Godley; John Cunningham; M Eileen Dolan; R Stephanie Huang; Sandeep Gurbuxani; Megan E McNerney; Richard A Larson; Hoyee Leong; Yves Lussier; Kenan Onel; Olatoyosi Odenike; Wendy Stock; Kevin P White; Michelle M Le Beau Journal: Semin Oncol Date: 2011-04 Impact factor: 4.929
Authors: Miralem Mrkonjic; Nicole M Roslin; Celia M Greenwood; Stavroula Raptis; Aaron Pollett; Peter W Laird; Vaijayanti V Pethe; Theodore Chiang; Darshana Daftary; Elizabeth Dicks; Stephen N Thibodeau; Steven Gallinger; Patrick S Parfrey; H Banfield Younghusband; John D Potter; Thomas J Hudson; John R McLaughlin; Roger C Green; Brent W Zanke; Polly A Newcomb; Andrew D Paterson; Bharati Bapat Journal: PLoS One Date: 2010-10-13 Impact factor: 3.240
Authors: Nathan A Ellis; Dezheng Huo; Ozlem Yildiz; Lisa J Worrillow; Mekhala Banerjee; Michelle M Le Beau; Richard A Larson; James M Allan; Kenan Onel Journal: Blood Date: 2008-04-21 Impact factor: 22.113